A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice

European Journal of Immunology

Volumn 44, Issue 7, 2014, Pages 1936-1946

  Kim, Sojung ^a   Pinto, Amelia K ^a   Myers, Nancy B ^a   Hawkins, Oriana ^b,c   Doll, Krysten ^b,c   Kaabinejadian, Saghar ^d   Netland, Jason ^e   Bevan, Michael J ^e   Weidanz, Jon A ^b,c   Hildebrand, William H ^d   Diamond, Michael S ^a   Hansen, Ted H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Receptor Logic Inc   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presentation; Cytotoxic T lymphocytes; Flavivirus; T cell receptor mimic

Indexed keywords

ANTIGEN PRESENTATION; CYTOTOXIC T LYMPHOCYTES; FLAVIVIRUS; T-CELL RECEPTOR MIMIC;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD11C; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; VIRAL NONSTRUCTURAL PROTEINS; WEST NILE VIRUS;

EID: 84904400214     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444450     Document Type: Article

References (54)

1. Yewdell, J. W., Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006. 25: 533-543.
2. Karosiene, E., Lundegaard, C., Lund, O. and Nielsen, M., NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 2012. 64: 177-186.
3. Lin, H. H., Zhang, G. L., Tongchusak, S., Reinherz, E. L. and Brusic, V., Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinform. 2008. 9(Suppl 12): S22.
4. Diez-Rivero, C. M., Lafuente, E. M. and Reche, P. A., Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome. BMC Bioinform. 2010. 11: 479.
5. + T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008. 28: 859-869.
6. Kotturi, M. F., Scott, I., Wolfe, T., Peters, B., Sidney, J., Cheroutre, H., von Herrath, M. G. et al., Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J. Immunol. 2008. 181: 2124-2133.
7. Flesch, I. E., Woo, W. P., Wang, Y., Panchanathan, V., Wong, Y. C., La Gruta, N. L., Cukalac, T. et al., Altered CD8(+) T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice. J. Immunol. 2010. 184: 45-55.
8. Tan, A. C., La Gruta, N. L., Zeng, W. and Jackson, D. C., Precursor frequency and competition dictate the HLA-A2-restricted CD8+ T cell responses to influenza A infection and vaccination in HLA-A2.1 transgenic mice. J. Immunol. 2011. 187: 1895-1902.
9. Yewdell, J. W., The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol. Rev. 2005. 207: 8-18.
10. Henderson, R. A., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F. and Engelhard, V. H., HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992. 255: 1264-1266.
11. Herr, W., Ranieri, E., Gambotto, A., Kierstead, L. S., Amoscato, A. A., Gesualdo, L. and Storkus, W. J., Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc. Natl. Acad. Sci. USA 1999. 96: 12033-12038.
12. Lucchiari-Hartz, M., van Endert, P. M., Lauvau, G., Maier, R., Meyerhans, A., Mann, D., Eichmann, K. et al., Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J. Exp. Med. 2000. 191: 239-252.
13. Flyer, D. C., Ramakrishna, V., Miller, C., Myers, H., McDaniel, M., Root, K., Flournoy, C. et al., Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product. Infect. Immun. 2002. 70: 2926-2932.
14. Samino, Y., Lopez, D., Guil, S., Saveanu, L., van Endert, P. M. and Del Val, M., A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural ligands from HIV envelope protein. J. Biol. Chem. 2006. 281: 6358-6365.
15. McMurtrey, C. P., Lelic, A., Piazza, P., Chakrabarti, A. K., Yablonsky, E. J., Wahl, A., Bardet, W. et al., Epitope discovery in West Nile virus infection: identification and immune recognition of viral epitopes. Proc. Natl. Acad. Sci. USA 2008. 105: 2981-2986.
16. Suthar, M. S., Diamond, M. S. and Gale, M., Jr., West Nile virus infection and immunity. Nat. Rev. Microbiol. 2013. 11: 115-128.
17. Brien, J. D., Uhrlaub, J. L. and Nikolich-Zugich, J., Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur. J. Immunol. 2007. 37: 1855-1863.
18. Purtha, W. E., Myers, N., Mitaksov, V., Sitati, E., Connolly, J., Fremont, D. H., Hansen, T. H. et al., Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur. J. Immunol. 2007. 37: 1845-1854.
19. Dahan, R. and Reiter, Y., T-cell-receptor-like antibodies-generation, function and applications. Expert. Rev. Mol. Med. 2012. 14: e6.
20. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R. and Germain, R. N., Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997. 6: 715-726.
21. Weidanz, J. A., Hawkins, O., Verma, B. and Hildebrand, W. H., TCR-like biomolecules target peptide/MHC class I complexes on the surface of infected and cancerous cells. Int. Rev. Immunol. 2011. 30: 328-340.
22. Samuel, M. A. and Diamond, M. S., Type I IFN protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 2005. 79: 13350-13361.
23. Oliphant, T., Engle, M., Nybakken, G., Doane, C., Johnson, S., Huang, L., Gorlatov, S. et al., Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 2005. 11: 522-530.
24. Oliphant, T., Nybakken, G. E., Engle, M., Xu, Q., Nelson, C. A., Sukupolvi-Petty, S., Marri, A. et al., Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 2006. 80: 12149-12159.
25. Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B. et al., Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008. 322: 1097-1100.
26. Samuel, M. A., Whitby, K., Keller, B. C., Marri, A., Barchet, W., Williams, B. R. G., Silverman, R. H. et al., PKR and RNAse L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 2006. 80: 7009-7019.
27. Purtha, W. E., Chachu, K. A., Virgin, H. W. and Diamond, M. S., Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J. Virol. 2008. 82: 10964-10974.
28. Shrestha, B., Wang, T., Samuel, M. A., Whitby, K., Craft, J., Fikrig, E. and Diamond, M. S., Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 2006. 80: 5338-5348.
29. Ekeruche-Makinde, J., Miles, J. J., van den Berg, H. A., Skowera, A., Cole, D. K., Dolton, G., Schauenburg, A. J. et al., Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood 2013. 121: 1112-1123.
30. Miles, J. J., Elhassen, D., Borg, N. A., Silins, S. L., Tynan, F. E., Burrows, J. M., Purcell et al., CTL recognition of a bulged viral peptide involves biased TCR selection. J. Immunol. 2005. 175: 3826-3834.
31. Tynan, F. E., Burrows, S. R., Buckle, A. M., Clements, C. S., Borg, N. A., Miles, J. J., Beddoe, T. et al., T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat. Immunol. 2005. 6: 1114-1122.
32. Collins, E. J., Garboczi, D. N. and Wiley, D. C., Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 1994. 371: 626-629.
33. Mitaksov, V., Truscott, S. M., Lybarger, L., Connolly, J. M., Hansen, T. H. and Fremont, D. H., Structural engineering of pMHC reagents for T cell vaccines and diagnostics. Chem. Biol. 2007. 14: 909-922.
34. Tynan, F. E., Reid, H. H., Kjer-Nielsen, L., Miles, J. J., Wilce, M. C., Kostenko, L., Borg, N. A. et al., A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat. Immunol. 2007. 8: 268-276.
35. Biddison, W. E., Turner, R. V., Gagnon, S. J., Lev, A., Cohen, C. J. and Reiter, Y., Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. J. Immunol. 2003. 171: 3064-3074.
36. Yamano, Y., Cohen, C. J., Takenouchi, N., Yao, K., Tomaru, U., Li, H. C., Reiter, Y. et al., Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4 +CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J. Exp. Med. 2004. 199: 1367-1377.
37. Sastry, K. S., Too, C. T., Kaur, K., Gehring, A. J., Low, L., Javiad, A., Pollicino, T. et al., Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J. Virol. 2011. 85: 1935-1942.
38. Herschhorn, A., Marasco, W. A. and Hizi, A., Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C. J. Immunol. 2010. 185: 7623-7632.
39. Makler, O., Oved, K., Netzer, N., Wolf, D. and Reiter, Y., Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity. Eur. J. Immunol. 2010. 40: 1552-1565.
40. Nunoya, J., Nakashima, T., Kawana-Tachikawa, A., Kiyotani, K., Ito, Y., Sugimura, K. and Iwamoto, A., Short communication: generation of recombinant monoclonal antibodies against an immunodominant HLA-A*2402-restricted HIV type 1 CTL epitope. AIDS Res. Hum. Retroviruses 2009. 25: 897-904.
41. Kim, S., Li, L., McMurtrey, C. P., Hildebrand, W. H., Weidanz, J. A., Gillanders, W. E., Diamond, M. S. et al., Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J. Immunol. 2010. 184: 4423-4430.
42. Allan, R. S., Smith, C. M., Belz, G. T., van Lint, A. L., Wakim, L. M., Heath, W. R. and Carbone, F. R., Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 2003. 301: 1925-1928.
43. Belz, G. T., Shortman, K., Bevan, M. J. and Heath, W. R., CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J. Immunol. 2005. 175: 196-200.
44. Allan, R. S., Waithman, J., Bedoui, S., Jones, C. M., Villadangos, J. A., Zhan, Y., Lew, A. M. et al., Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006. 25: 153-162.
45. Thompson, B. S., Moesker, B., Smit, J. M., Wilschut, J., Diamond, M. S. and Fremont, D. H., A therapeutic antibody against West Nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 2009. 5: e1000453.
46. Youn, S., Ambrose, R. L., Mackenzie, J. M. and Diamond, M. S., Non-structural protein-1 is required for West Nile virus replication complex formation and viral RNA synthesis. Virol. J. 2013. 10: 339.
47. Brinton, M. A., The molecular biology of West Nile virus: a new invader of the western hemisphere. Annu. Rev. Microbiol. 2002. 56: 371-402.
48. Ginhoux, F., Liu, K., Helft, J., Bogunovic, M., Greter, M., Hashimoto, D., Price, J. et al., The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 2009. 206: 3115-3130.
49. Edelson, B. T., Kc, W., Juang, R., Kohyama, M., Benoit, L. A., Klekotka, P. A., Moon, C. et al., Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J. Exp. Med. 2010. 207: 823-836.
50. Helft, J., Manicassamy, B., Guermonprez, P., Hashimoto, D., Silvin, A., Agudo, J., Brown, B. D. et al., Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J. Clin. Invest. 2012. 122: 4037-4047.
51. Dolan, B. P., Gibbs, K. D., Jr. and Ostrand-Rosenberg, S., Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J. Immunol. 2006. 177: 6018-6024.
52. Wakim, L. M. and Bevan, M. J., Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature 2011. 471: 629-632.
53. Li, L., Kim, S., Herndon, J. M., Goedegebuure, P., Belt, B. A., Satpathy, A. T., Fleming, T. P. et al., Cross-dressed CD8alpha+/CD103+ dendritic cells prime CD8+ T cells following vaccination. Proc. Natl. Acad. Sci. USA 2012. 109: 12716-12721.
54. Hammerling, G. J., Lemke, H., Hammerling, U., Hohmann, C., Wallich, R. and Rajewsky, K., Monoclonal antibodies against murine cell surface antigens: anti-H-2, anti-Ia and anti-T cell antibodies. Curr. Top Microbiol. Immunol. 1978. 81: 100-106.